Hengrui Medicine (600276.SH) signs strategic cooperation and licensing agreement with Novartis AG company.

Techfin News APP: Hengrui Medicine (600276.SH) announced that the company has reached a global strategic cooperation and licensing agreement with Bristol-Myers Squibb Company (referred to as "BMS" below) to jointly promote 13 early-stage projects in oncology, hematology, and immunology, accelerating the research and development of innovative drugs and benefiting patients worldwide.